This company has been acquired
CARGO Therapeutics (CRGX) Stock Overview
A clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CRGX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CARGO Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.47 |
| 52 Week High | US$25.45 |
| 52 Week Low | US$3.00 |
| Beta | 0 |
| 1 Month Change | -1.11% |
| 3 Month Change | 9.02% |
| 1 Year Change | -74.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.24% |
Recent News & Updates
Recent updates
Here's Why We're Watching CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn Situation
Mar 26
CARGO Therapeutics: A Gutted CAR T Player Trying To Find New Direction
Mar 03Here's Why We're Not Too Worried About CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn Situation
Nov 28CARGO Therapeutics (NASDAQ:CRGX) Is In A Good Position To Deliver On Growth Plans
May 10Cargo Therapeutics: High Venture Interest But Still Early Days For This CAR-T Player
Jan 28Shareholder Returns
| CRGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 1.4% | -0.9% |
| 1Y | -74.3% | 27.5% | 12.5% |
Return vs Industry: CRGX underperformed the US Biotechs industry which returned -8.1% over the past year.
Return vs Market: CRGX underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| CRGX volatility | |
|---|---|
| CRGX Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRGX's weekly volatility has decreased from 14% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 167 | Anup Radhakrishnan | cargo-tx.com |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022.
CARGO Therapeutics, Inc. Fundamentals Summary
| CRGX fundamental statistics | |
|---|---|
| Market cap | US$216.19m |
| Earnings (TTM) | -US$221.78m |
| Revenue (TTM) | n/a |
Is CRGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRGX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$221.78m |
| Earnings | -US$221.78m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/20 15:25 |
| End of Day Share Price | 2025/08/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CARGO Therapeutics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Robert Burns | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |